PR binding studies were also performed in T47D breast cancer cells and in primary leiomyoma cells stimulated with the selective progesterone receptor modulator, RU486, which has mixed PR agonist and antagonist activities [38]. This evidence concerns the gene PGR and breast carcinoma.